fostamatinib · Tavalisse

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Immune Thrombocytopenia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (4)
BR
  • Tavalisse (fostamatinib); licensee Knight Therapeutics
Product first approved 2026bnnbloomberg.ca
JP
  • Tavalisse tablets 100 mg and 150 mg for chronic idiopathic thrombocytopenic purpura (chronic ITP); holder Kissei
Product first approved 2022rigel.com
CA
  • Tavalisse for thrombocytopenia in adults with chronic ITP with insufficient response to other treatments
Product first approved 2020rigel.com
EU
  • Tavlesse: chronic immune thrombocytopenia (ITP) in adults refractory to other treatments; holder Instituto Grifols S.A.
Product first approved 2020EMA

Development in Rheumatoid Arthritis stopped as a strategic decision by the sponsor. Source

Development in Systemic Lupus Erythematosus stopped as a strategic decision by the sponsor. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (10)
Other / comorbidity
NCT04138927 · Rigel Pharmaceuticals
2019-10-30 – 2024-04 · Warm Antibody Autoimmune Hemolytic Anemia
What this study did
NCT04629703 · Rigel Pharmaceuticals
2021-03-25 – 2022-09-05 · Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
What this study did
NCT03764618 · Rigel Pharmaceuticals
2019-04-24 – 2022-04-11 · Warm Antibody Autoimmune Hemolytic Anemia
What this study did
NCT02077192 · Rigel Pharmaceuticals
2014-10 – 2020-06-02 · Immune Thrombocytopenic Purpura
What this study did
NCT01242514 · AstraZeneca
2011-01 – 2015-01 · Rheumatoid Arthritis
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT04924660 · Sean Collins
2021-07-15 – 2023-12-31 · COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
What this study did
NCT05593770 · NEAT ID Foundation
2022-10-27 – 2023-12-14 · COVID-19, SARS-CoV2 Infection, Coronavirus Infection
What this study did
Phase 2 (22)
Other / comorbidity
NCT06564207 · Inova Health Care Services
2026-11-30 – 2027-10-31 · Acute Respiratory Distress Syndrome, ARDS
What this study did
NCT05509582 · National Heart, Lung, and Blood Institute (NHLBI)
2025-11-07 – 2025-11-07 · Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
What this study did
NCT05502783 · National Heart, Lung, and Blood Institute (NHLBI)
2023-03-10 – 2023-06-16 · Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
What this study did
NCT05040698 · Holdsworth House Medical Practice
2021-10-01 – 2023-01-27 · Hidradenitis Suppurativa
What this study did
NCT04543279 · Washington University School of Medicine
2021-05-03 – 2022-07-30 · Myelofibrosis, Thrombocytopenia
What this study did
NCT04579393 · National Heart, Lung, and Blood Institute (NHLBI)
2020-10-08 – 2021-04-30 · Coronavirus Disease 2019
What this study did
NCT02612558 · Rigel Pharmaceuticals
2016-07 – 2019-12 · Warm Antibody Autoimmune Hemolytic Anemia
What this study did
NCT02112838 · Rigel Pharmaceuticals
2014-10 – 2018-11-12 · IGA Nephropathy
What this study did
NCT02433236 · Rigel Pharmaceuticals
2015-09 – 2015-09 · IGA Nephropathy
What this study did
NCT01499303 · AstraZeneca
2011-12 – 2013-10 · Diffuse Large B-Cell Lymphoma
What this study did
NCT00805467 · AstraZeneca
2008-08 – 2013-08 · Rheumatoid Arthritis
What this study did
NCT01264770 · AstraZeneca
2011-01 – 2013-08 · Rheumatoid Arthritis
What this study did
NCT01640054 · AstraZeneca
2012-07 – 2013-07 · Rheumatoid Arthritis
What this study did
NCT01569074 · AstraZeneca
2012-04 – 2013-07 · Rheumatoid Arthritis
What this study did
NCT02092961 · AstraZeneca
2011-02 – 2013-07 · Rheumatoid Arthritis
What this study did
NCT01563978 · AstraZeneca
2012-04 – 2013-01 · Rheumatoid Arthritis
What this study did
NCT00923481 · National Cancer Institute (NCI)
2009-04 – 2012-01 · Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
What this study did
NCT00706342 · Rigel Pharmaceuticals
2007-01 – 2010-04 · Purpura, Thrombocytopenic, Idiopathic
What this study did
NCT00798096 · Rigel Pharmaceuticals
2009-03 – 2010-04 · T Cell Lymphoma
What this study did
NCT00752999 · Rigel Pharmaceuticals
2008-11 – 2010-03 · Systemic Lupus Erythematosus
What this study did
NCT00665925 · Rigel Pharmaceuticals
2008-05 – 2009-06 · Rheumatoid Arthritis
What this study did
NCT00665626 · Rigel Pharmaceuticals
2008-05 – 2009-06 · Rheumatoid Arthritis
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT03991780 · Imperial College London
2019-05-08 – 2025-10-15 · Renal Transplant Rejection
What this study did
NCT04581954 · Imperial College London
2020-10-02 – 2023-09-02 · Coronavirus, Covid19, Pneumonia
What this study did
NCT00446095 · Rigel Pharmaceuticals
2007-04 – 2010-10 · Lymphoma
What this study did
Phase 1 (22)
Other / comorbidity
NCT06233110 · Stefanie Sarantopoulos, MD, PhD.
2025-10-29 – 2029-07-01 · Chronic Graft Versus Host Disease
What this study did
NCT06639724 · University of California, San Diego
2024-12-05 – 2028-12 · Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT06948097 · National Heart, Lung, and Blood Institute (NHLBI)
2026-11-24 – 2028-07-14 · Lung Transplantation
What this study did
NCT05904093 · National Heart, Lung, and Blood Institute (NHLBI)
2024-12-18 – 2027-05-14 · Sickle Cell Disorders, Sickle Cell Disease, Hemoglobin S, Hb-SS Disease, Disease Sickle Cell Anemia
What this study did
NCT05030675 · M.D. Anderson Cancer Center
2021-08-13 – 2024-08-08 · Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT03246074 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-04-03 – 2023-04-03 · Ovarian Cancer
What this study did
NCT02611063 · Stefanie Sarantopoulos, MD, PhD.
2016-01 – 2022-02-22 · Hematological Malignancies
What this study did
NCT01645085 · AstraZeneca
2012-07 – 2013-03 · Healthy Volunteers
What this study did
NCT01725230 · AstraZeneca
2012-11 – 2013-01 · Rheumatoid Arthritis
What this study did
NCT01682408 · AstraZeneca
2012-09 – 2012-12 · Pharmacokinetics
What this study did
NCT01598571 · AstraZeneca
2012-05 – 2012-08 · Healthy
What this study did
NCT01608542 · AstraZeneca
2012-06 – 2012-08 · Healthy Japanese Volunteers
What this study did
NCT01276262 · AstraZeneca
2011-03 – 2011-11 · Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction, Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction
What this study did
NCT01387308 · AstraZeneca
2011-08 – 2011-10 · Healthy
What this study did
NCT01355354 · AstraZeneca
2011-06 – 2011-09 · Healthy Volunteers, Rheumatoid Arthritis
What this study did
NCT01336218 · AstraZeneca
2011-04 – 2011-07 · Rheumatoid Arthritis, Healthy Volunteers
What this study did
NCT01245790 · AstraZeneca
2010-11 – 2011-06 · Rheumatoid Arthritis, Renal Impairment
What this study did
NCT01222455 · AstraZeneca
2010-10 – 2011-06 · Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
What this study did
NCT01309854 · AstraZeneca
2011-03 – 2011-05 · Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone, Drug-drug Interaction, Amount of Pioglitazone in Blood
What this study did
NCT01311622 · AstraZeneca
2011-03 – 2011-05 · Rheumatoid Arthritis, Healthy Subjects
What this study did
NCT01208155 · AstraZeneca
2010-09 – 2010-11 · Bioavailability, Pharmacokinetics
What this study did

Competitive landscape

This drug's own stage for Immune Thrombocytopenia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fostamatinib (Tavalisse): this drugApprovedSmall moleculeSpleen tyrosine kinase (Syk)not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibApprovedSmall moleculeBTKReliable signalNo reviewed efficacy summary in this indication
CID-103Phase 2Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tavalisse (fostamatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (2)
Phase 1Sickle Cell Disorders, Sickle Cell Disease, Hemoglobin S, Hb-SS Disease, Disease Sickle Cell AnemiaRecruiting
Est. primary completion 2027-05-14 · NCT05904093 · CT.gov ↗
What to watch
Phase 2Acute Respiratory Distress Syndrome, ARDSNot yet recruiting
Est. primary completion 2027-05-31 · NCT06564207 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
Est. primary completion 2027-12 · NCT06639724 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 1Lung TransplantationRecruiting
Est. primary completion 2028-07-14 · NCT06948097 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 1Chronic Graft Versus Host DiseaseRecruiting
Est. primary completion 2029-01-01 · NCT06233110 · CT.gov ↗
What to watch

See the full readout calendar ↗